{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3690, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 63, "slideType": "solution", "function": "present_solution", "notes": "The slide illustrates the mechanism of action for two therapeutic modalities derived from the same TCR discovery platform.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/63", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-63", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 64, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a comparative framework to explain the safety profile of their technology platform.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/64", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-64", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 65, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a flywheel-style circular diagram to represent the iterative nature of the data platform.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/65", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-65", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 66, "slideType": "unfair_advantage", "function": "establish_context", "notes": "The slide highlights the breadth of the company's intellectual property protection across major global regions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/66", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-66", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 67, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/67", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-67", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 68, "slideType": "team_bio", "function": "other", "notes": "The slide uses a grid layout with headshots and professional titles for 9 executives.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/68", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-68", "loopMatches": [], "arcBeatMatches": [ { "to": 69, "from": 68, "beatId": "87fef79a-e9ef-4ca0-bd81-324a4834bfea", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "The team is presented in the team bio and geographic map sections.", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 69, "slideType": "geographic_map", "function": "establish_context", "notes": "The slide highlights the trans-atlantic nature of the organization with specific operational focus areas per site.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/69", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-69", "loopMatches": [], "arcBeatMatches": [ { "to": 69, "from": 68, "beatId": "87fef79a-e9ef-4ca0-bd81-324a4834bfea", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "The team is presented in the team bio and geographic map sections.", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 70, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/70", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-70", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 71, "slideType": "traction", "function": "analyze_data", "notes": "Includes waterfall plot and spider plot for RECIST 1.1 response metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/71", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-71", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 72, "slideType": "traction", "function": "show_traction", "notes": "Includes waterfall plot and spider plot (change in tumor size over time).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/72", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-72", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 73, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data cut-off Sep 30, 2023. N=21 patients.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/73", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-73", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 74, "slideType": "appendix_data", "function": "analyze_data", "notes": "Data cut-off Sep 30, 2023. N=28 patients.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/74", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-74", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-48c2-7315-bf77-72d2721572a4", "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91", "documentTitle": "Immatics | Investor Presentation Deck | 75 slides", "authorId": "immatics", "authorName": "Immatics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 75, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/75", "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4", "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-75", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Includes date and ticker symbol.", "imagePath": "https://imgproxy.kitesheet.com/-thmQLWbxDjVNTddMDzyfE6CqappHQJZ0P7BfipHt_o/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNGZjNTE2OTM5OWY4OTEzYzU0ZjE0ZDE4MDMxNjI5Yy9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/1", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/Ik1WICk9cNQlUWsusSFaAHH2adMiB-P_y-YdOCeP9GE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNGZjNTE2OTM5OWY4OTEzYzU0ZjE0ZDE4MDMxNjI5Yy9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/Oo29jX8EglSXR-yHmQfl1ezr1sdUjKgzVEEIzpQu5Cc/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNGZjNTE2OTM5OWY4OTEzYzU0ZjE0ZDE4MDMxNjI5Yy9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/9ViTsbk2Ft1qHCXQbljGttsG8nfyGQY4jS1fLWmiTJs/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hNGZjNTE2OTM5OWY4OTEzYzU0ZjE0ZDE4MDMxNjI5Yy9wMDAxLnBuZw" }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/2", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/3", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-3", "loopMatches": [ { "to": 3, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "820ce5c0-3f93-4376-98b0-b2a31384205a", "evidence": "The investment highlights section provides an overview of the company's value proposition.", "position": 1, "objective": "Why is Immix Biopharma's approach important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "team_bio", "function": "other", "notes": "The slide uses a structured grid layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/4", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/5", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "2c898a09-dcbd-4e71-b1a9-74c960574c7f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The N-GENIUS platform and proprietary technologies are presented as solutions.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "solution", "function": "present_solution", "notes": "Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Overcoming neurotoxicity'.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/6", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "2c898a09-dcbd-4e71-b1a9-74c960574c7f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The N-GENIUS platform and proprietary technologies are presented as solutions.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "problem_statement", "function": "frame_problem", "notes": "Includes a cartoon illustration of a cell/virus character.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/7", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-7", "loopMatches": [ { "to": 7, "from": 7, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "117488b9-d6ba-45dd-8fb1-95a97c0e2509", "evidence": "The problem statement highlights the limitations of current CAR-T therapies.", "position": 0, "objective": "What are the consequences of not addressing neurotoxicity in CAR-T therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 7, "from": 7, "beatId": "389cbce4-81e4-4aab-8750-85f4419a53ee", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "The problem of neurotoxicity restricting CAR-T adoption is clearly stated.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 9, "from": 5, "beatId": "2c898a09-dcbd-4e71-b1a9-74c960574c7f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The N-GENIUS platform and proprietary technologies are presented as solutions.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/8", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "2c898a09-dcbd-4e71-b1a9-74c960574c7f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The N-GENIUS platform and proprietary technologies are presented as solutions.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a diagram to map specific protein domains to their functional benefits.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/9", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 5, "beatId": "2c898a09-dcbd-4e71-b1a9-74c960574c7f", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The N-GENIUS platform and proprietary technologies are presented as solutions.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/10", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-10", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-201.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/11", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-11", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "solution", "function": "present_solution", "notes": "The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations, demonstrating superior performance for HSL.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/12", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-12", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "solution", "function": "present_solution", "notes": "Includes a cartoon mascot at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/13", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-13", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/14", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-14", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "unfair_advantage", "function": "present_solution", "notes": "The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/15", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-15", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "solution", "function": "present_solution", "notes": "Includes comparative data points for transduction efficiency and experimental data for signaling and exhaustion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/16", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-16", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a multi-panel line chart to compare clinical outcomes across three different therapies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/17", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-17", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates the mechanism of action: rapid cell expansion followed by clearance within 30 days, correlating with disease marker reduction.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/18", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 22, "from": 18, "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Clinical results and progress are highlighted.", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a causal chain framework to link cellular pathology to systemic organ damage.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/19", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 22, "from": 18, "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Clinical results and progress are highlighted.", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a grouped bar chart format to compare clinical outcomes across different therapeutic agents.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/20", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 22, "from": 18, "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Clinical results and progress are highlighted.", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses a table to contrast treatment efficacy and patient growth across disease stages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/21", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 22, "from": 18, "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Clinical results and progress are highlighted.", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/22", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-22", "loopMatches": [], "arcBeatMatches": [ { "to": 22, "from": 18, "beatId": "b9896073-6be4-4e40-b3ed-41f8f273601a", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Traction", "beatSlug": null, "evidence": "Clinical results and progress are highlighted.", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes FDA approval precedents as a footnote to justify the clinical strategy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/23", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 27, "from": 23, "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The clinical development plan and upcoming catalysts are outlined.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Uses a visual icon-grid to represent market expansion.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/24", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 29, "from": 24, "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": "sequoia-pitch-market-size", "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 27, "from": 23, "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The clinical development plan and upcoming catalysts are outlined.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "traction", "function": "show_traction", "notes": "Includes detailed clinical trial citations in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/25", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 29, "from": 24, "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": "sequoia-pitch-market-size", "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 27, "from": 23, "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The clinical development plan and upcoming catalysts are outlined.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a two-column layout to separate milestones by drug candidate.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/26", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-26", "loopMatches": [], "arcBeatMatches": [ { "to": 29, "from": 24, "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": "sequoia-pitch-market-size", "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 27, "from": 23, "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The clinical development plan and upcoming catalysts are outlined.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "roadmap", "function": "show_traction", "notes": "The slide uses a standard pharmaceutical pipeline table format, categorizing by clinical vs preclinical status and highlighting specific regulatory designations and trial results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/27", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-27", "loopMatches": [], "arcBeatMatches": [ { "to": 29, "from": 24, "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": "sequoia-pitch-market-size", "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 27, "from": 23, "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Roadmap", "beatSlug": null, "evidence": "The clinical development plan and upcoming catalysts are outlined.", "position": 4, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "market_sizing", "function": "size_opportunity", "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/28", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-28", "loopMatches": [], "arcBeatMatches": [ { "to": 29, "from": 24, "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": "sequoia-pitch-market-size", "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a visual wave/area chart metaphor to represent market segments and their respective valuations.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/29", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-29", "loopMatches": [], "arcBeatMatches": [ { "to": 29, "from": 24, "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Sizing", "beatSlug": "sequoia-pitch-market-size", "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/30", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-30", "loopMatches": [ { "to": 30, "from": 30, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "0b3e815d-9465-48f9-910b-a6943e26c1a5", "evidence": "The market sizing section discusses the potential for Immix Biopharma's therapies.", "position": 2, "objective": "What are the opportunities for growth and expansion?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/31", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/32", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table compares NXC-201 against various CAR-T therapies, highlighting patient characteristics, efficacy (ORR, CR), and safety (ICANS, CRS) metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/33", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/34", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates deepening clinical response over time for NXC-201 therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/35", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management interventions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/36", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "comparison_table", "function": "compare_peers", "notes": "The table highlights specific clinical safety metrics including onset and duration for CRS and ICANS, as well as the use of Tocilizumab and Dexamethasone.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/37", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/38", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "section_divider", "function": "transition", "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug's mechanism of action or target environment.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/39", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "solution", "function": "present_solution", "notes": "Includes scientific diagrams of molecular pathways, penetration depth charts, and efficacy metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/40", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-40", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "traction", "function": "show_traction", "notes": "Slide contains three distinct charts comparing IMX-110 against standard of care in mouse models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/41", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-41", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "other", "function": "illustrate_case", "notes": "Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/42", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-42", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "traction", "function": "show_traction", "notes": "Includes survival curves (Kaplan-Meier style), median survival bar charts, and bioluminescence imaging of tumor activity.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/43", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-43", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/44", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-44", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "traction", "function": "show_traction", "notes": "The slide compares sarcoma patients against non-sarcoma patients using line charts for lesion size change and a bar chart for best percentage change.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/45", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-45", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "problem_statement", "function": "frame_problem", "notes": "The bubble chart maps mPFS against patient treatment history; the table highlights poor outcomes and high toxicity across lines of therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/46", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-46", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-495e-7269-8bd5-c9a0e886c917", "docSlug": "a4fc5169399f8913c54f14d18031629c", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "traction", "function": "show_traction", "notes": "The slide presents clinical data for a small sample size (n=4).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/47", "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917", "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-47", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }